Netherlands' Argenx Q3 sales jump on strong VYVGART demand
Netherlands' Argenx Q3 sales jump on strong VYVGART demand
Overview
Netherlands immunology drug developer's Q3 net sales rose 54% yr/yr to $1.7 bln
Q3 net profit and basic EPS increased yr/yr
Company attributes growth to VYVGART sales and expansion into new indications
Outlook
Company expects 2026 combined R&D and SG&A expenses to be about $4 bln
argenx plans sBLA submission for VYVGART Hytrulo in IMNM by end-2026
Topline Phase 3 MMN data for empasiprubart expected in Dec 2026
Result Drivers
VYVGART SALES - Co said strong Q3 results were driven by continued performance of VYVGART in gMG and CIDP
NEW INDICATIONS - Positive Phase 3 results and regulatory progress for VYVGART in IMNM and DM supported sales growth
COMMERCIALIZATION EXPENSES - Increased SG&A expenses linked to global commercialization of VYVGART franchise
Company press release: ID:nGNE88HgPH
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 EPS |
| $7.80 |
|
Q3 Net Income |
| $506 mln |
|
Q3 Basic EPS |
| $8.07 |
|
Q3 Operating Expenses |
| $1.27 bln |
|
Q3 Total Operating Income |
| $1.75 bln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for argenx SE is €996.00, about 26.6% above its October 21 closing price of €786.60
The stock recently traded at 24 times the next 12-month earnings vs. a P/E of 29 three months ago
Reuters Recommended Reads
Oct 19 - Germany's Merck buys Silence Therapeutics in $1.3 billion RNA drug deal
Oct 19 - HK-listed Metis TechBio, Eli Lilly strike drug-delivery deal worth up to $1.1 billion
Oct 20 - US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)